Nuvation Bio Inc.
Graf
Viktig: Aksjeinvesteringer kan over tid gi positiv avkastning, men innebærer risiko. Du kan tape deler av eller hele investeringen. Historisk avkastning for denne aksjen er ikke en pålitelig indikator på fremtidig avkastning. Data fra eksterne leverandører gjengis uendret av Saxo. Se fullstendig ansvarsfraskrivelse for data.
Om Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
/ 